The DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index.
Parkinson's disease
Open accessAbstract
Parkinson's disease is a recognisable clinical syndrome with a range of causes and clinical presentations. Parkinson's disease represents a fast-growing neurodegenerative condition; the rising prevalence worldwide resembles the many characteristics typically observed during a pandemic, except for an infectious cause. In most populations, 3-5% of Parkinson's disease is explained by genetic causes linked to known Parkinson's disease genes, thus representing monogenic Parkinson's disease, whereas 90 genetic risk variants collectively explain 16-36% of the heritable risk of non-monogenic Parkinson's disease. Additional causal associations include having a relative with Parkinson's disease or tremor, constipation, and being a non-smoker, each at least doubling the risk of Parkinson's disease. The diagnosis is clinically based; ancillary testing is reserved for people with an atypical presentation. Current criteria define Parkinson's disease as the presence of bradykinesia combined with either rest tremor, rigidity, or both. However, the clinical presentation is multifaceted and includes many non-motor symptoms. Prognostic counselling is guided by awareness of disease subtypes. Clinically manifest Parkinson's disease is preceded by a potentially long prodromal period. Presently, establishment of prodromal symptoms has no clinical implications other than symptom suppression, although recognition of prodromal parkinsonism will probably have consequences when disease-modifying treatments become available. Treatment goals vary from person to person, emphasising the need for personalised management. There is no reason to postpone symptomatic treatment in people developing disability due to Parkinson's disease. Levodopa is the most common medication used as first-line therapy. Optimal management should start at diagnosis and requires a multidisciplinary team approach, including a growing repertoire of non-pharmacological interventions. At present, no therapy can slow down or arrest the progression of Parkinson's disease, but informed by new insights in genetic causes and mechanisms of neuronal death, several promising strategies are being tested for disease-modifying potential. With the perspective of people with Parkinson's disease as a so-called red thread throughout this Seminar, we will show how personalised management of Parkinson's disease can be optimised.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Strikingly, non-motor symptoms remain poorly responsive to current PD treatments despite being present from early prodromal PD and contributing significantly to overall disease burden [36].”
From The gut–brain axis in early Parkinson’s disease: from prodrome to prevention (2025) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical practice guidelines support resilience training and exercise for patients with Parkinson’s disease (PD).”
From A randomized clinical trial of mindfulness meditation versus exercise in Parkinson’s disease during social unrest (2023) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The diseases encompass various severe conditions, including neurodegenerative disorders like Alzheimer’s disease (AD) [3, 4] and Parkinson’s disease (PD) [5, 6], as well as traumatic brain injuries (TBI) [7] and spinal cord injuries (SCI) [8].”
From Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions (2024) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: Parkin and PINK1 mitigate STING-induced inflammation
Sliter, D. A., Martinez, J., Hao, L., Chen, X., Sun, N., Fischer, T. D., Burman, J. L., Li, Y., Zhang, Z., Narendra, D. P., et al. (2018) · Nature · doi:10.1038/s41586-018-0448-9 · Cited by 1,287
Self-citationRetractedStaging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
MDS clinical diagnostic criteria for Parkinson’s disease
Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., et al. (2015) · Movement Disorders · doi:10.1002/mds.26424 · Cited by 7,653
Self-citationKalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,184
Feigin, V. L., Nichols, E., Alam, T., Bannick, M. S., Beghi, E., Blake, N., Culpepper, W. J., Dorsey, E. R., Elbaz, A., Ellenbogen, R. G., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30499-x · Cited by 5,644
Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease
Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., Challis, C., Schretter, C. E., Rocha, S., Gradinaru, V., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.018 · Cited by 3,622
Huber, M., Knottnerus, J. A., Green, L., van der Horst, H. E., Jadad, A. R., Kromhout, D., Leonard, B. E., Lorig, K. R., Loureiro, I., Meer, J. W. M. V. D., et al. (2011) · BMJ · doi:10.1136/bmj.d4163 · Cited by 2,983
Diagnosis and Treatment of Parkinson Disease: A Review
Armstrong, M. J., & Okun, M. S. (2020) · JAMA · doi:10.1001/jama.2019.22360 · Cited by 2,924
Self-citationDorsey, E. R., Elbaz, A., Nichols, E., Abbasi, N., Abd-Allah, F., Abdelalim, A., Adsuar, J. C., Ansha, M. G., Brayne, C., Choi, J.-Y. J., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30295-3 · Cited by 2,816
Nalls, M. A., Blauwendraat, C., Vallerga, C. L., Heilbron, K., Bandres-Ciga, S., Chang, D., Tan, M., Kia, D. A., Noyce, A. J., Xue, A., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30320-5 · Cited by 2,454
Cited by
Sorted by citations
Items 901–1,000 of 1,004
Zhang, W., Liu, W., Zhao, Y., Xing, L.-Z., Xu, J. P., Li, R.-J., & Zhang, Y. (2023) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2023.129564 · Cited by 14
Yan, Y., Zheng, W., Wei, W., Yang, Z., Guo, L., Wang, Z., & Wei, X. (2023) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-23-267 · Cited by 14
Haas, A. N., Delabary, M. D. S., Monteiro, E. P., Wolffenbüttel, M., Donida, R. G., Casal, M. Z., Zanardi, A. P. J., Rodrigues, L. P., Martinez, F. G., & Peyré‐Tartaruga, L. A. (2023) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2023.105285 · Cited by 14
A new online Arabic handwriting dataset for analyzing Parkinson’s disease
Allebawi, M. F., Dhieb, T., Jarraya, I., Néji, M., Farhat, N., Smaoui, E., Moalla, K. S., Dammak, M., Hamdani, T. M., Mhiri, C., et al. (2023) · International Conference on Cyberworlds (CW) · doi:10.1109/cw58918.2023.00019 · Cited by 15
Pingale, T. D., & Gupta, G. L. (2023) · Toxicology Mechanisms and Methods · doi:10.1080/15376516.2023.2288198 · Cited by 14
Zhang, Z., Liu, N., Pan, X., Zhang, C., Yang, Y., Li, X., & Shao, Y. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1321246 · Cited by 15
Genetic landscape of Parkinson’s disease and related diseases in Luxembourg
Landoulsi, Z., Pachchek, S., Bobbili, D. R., Pavelka, L., May, P., & Krüger, R. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1282174 · Cited by 14
Zhou, X., Gao, Y. J., Wei, J., Luo, J., Wang, Y., Yue, M., Wang, B., Hong, D., Chen, T., & Fang, X. (2023) · Neurochemistry International · doi:10.1016/j.neuint.2023.105661 · Cited by 15
Wu, X., Yuan, R., Xu, Y., Wang, K., Yuan, H., Meng, T., & Hu, F. (2024) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2024.100904 · Cited by 16
Dopamine‑iron homeostasis interaction rescues mitochondrial fitness in Parkinson's disease
Buoso, C., Seifert, M., Lang, M., Griffith, C. M., Andújar, B. T., Rueda, M. P. C., Fischer, C., Doerrier, C., Talasz, H., Zanon, A., et al. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106506 · Cited by 16
Pauly, L., Rauschenberger, A., Pauly, C., Schröder, V. E., Cutsem, G. V., Leist, A. K., & Krüger, R. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-230285 · Cited by 12
Paradigm shift required for translational research on the brain
Yoon, J. H., Lee, D., Lee, C., Cho, E., Lee, S., Cazenave‐Gassiot, A., Kim, K., Chae, S., Dennis, E. A., & Suh, P. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01218-x · Cited by 14
Chen, Y., Qi, Y., Li, T., Lin, A., Ni, Y., Pu, R., & Sun, B. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1393841 · Cited by 14
Wang, B., Hu, X., Ge, R., Xu, C., Zhang, J., Gao, Z., Shu, Z., & Polat, K. (2024) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2024.102932 · Cited by 15
Exercise for People with Parkinson’s Disease: Updates and Future Considerations
McGinley, J. L., & Nakayama, Y. (2024) · Physical Therapy Research · doi:10.1298/ptr.r0030 · Cited by 14
Shen, Y., Chen, L., Liu, J., Chen, H., Wang, C., Ding, H., & Zhang, Q. (2025) · Computerized Medical Imaging and Graphics · doi:10.1016/j.compmedimag.2024.102490 · Cited by 14
Borzì, L., Demrozi, F., Bacchin, R. A., Turetta, C., Sigcha, L., Rinaldi, D., Fazzina, G., Balestro, G., Picelli, A., Pravadelli, G., et al. (2025) · Journal of Parkinson s Disease · doi:10.1177/1877718x241302766 · Cited by 17
Interaction Between Traffic-Related Air Pollution and Parkinson Disease Polygenic Risk Score
Kwon, D., Paul, K. C., Kusters, C., Wu, J. Y., Bronstein, J. M., Lill, C. M., Ketzel, M., Raaschou‐Nielsen, O., Hansen, J., & Ritz, B. R. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.0854 · Cited by 14
RNA‐Based Therapies for Neurodegenerative Diseases Targeting Pathogenic Proteins
Rabbani, S. A., El‐Tanani, M., Sharma, S., El‐Tanani, Y., Kumar, R., Saini, M., Yadav, M., Khan, M. A., & Parvez, S. (2025) · European Journal of Neuroscience · doi:10.1111/ejn.70110 · Cited by 15
Ravi, V., & Natarajan, C. (2025) · Scientific Reports · doi:10.1038/s41598-025-00898-3 · Cited by 14
Acteoside as a multifunctional natural glycoside: therapeutic potential across various diseases
Mohammed, R. A., Kamel, A. S. E. D., Hindam, M. O., El‐Dessouki, A. M., Hamouda, H. A., Ramadan, N. M., Mohamed, S. S., El‐Shiekh, R. A., & Kamel, N. M. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01811-0 · Cited by 14
Chaudhuri, К. R., Hand, A., Obam, F., & Belsey, J. (2022) · Journal of Medical Economics · doi:10.1080/13696998.2022.2080437 · Cited by 14
Yang, N., Ju, Y., Ren, J., Wang, H., Li, P., Ning, H., Tao, J., & Liu, W. (2022) · Acta Neurologica Scandinavica · doi:10.1111/ane.13662 · Cited by 13
Community Exercise: A New Tool for Personalized Parkinson’s Care or Just an Addition to Formal Care?
Domingos, J., Dean, J., Fernandes, J. B., Massano, J., & Godinho, C. (2022) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2022.916237 · Cited by 14
Lei, T., Xiao, Z., Zhang, X., Cai, S., Bi, W., Yang, Y., Wang, D., Li, Q., & Du, H. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2022.06.007 · Cited by 14
Subtyping of early-onset Parkinson’s disease using cluster analysis: A large cohort study
Zhou, Z., Zhou, X., Xiang, Y., Zhao, Y., Pan, H., Wu, J., Xu, Q., Chen, Y., Sun, Q., Wu, X., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1040293 · Cited by 14
Mitochondrial signaling on innate immunity activation in Parkinson disease
Magalhães, J. D., & Cardoso, S. M. (2022) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2022.102664 · Cited by 14
Lai, M.-C., Liu, W.-Y., Liou, S., & Liu, I.-M. (2023) · Nutrients · doi:10.3390/nu15030549 · Cited by 14
Qi, A., Liu, L., Zhang, J., Chen, S., Xu, S., Chen, Y., Zhang, L., & Cai, C. (2023) · Molecular Neurobiology · doi:10.1007/s12035-022-03157-y · Cited by 14
Cassidy, I., Doody, O., Richardson, M., & Meskell, P. (2024) · BMC Neurology · doi:10.1186/s12883-024-03769-y · Cited by 13
Yang, X., Gao, X., Jiang, X., Yue, K., & Luo, P. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00462 · Cited by 15
Zhao, J., Wu, Z., Cai, F., Yu, X., & Song, Z. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1529197 · Cited by 14
Guo, X., Wei, R., Yin, X., & Yang, G. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1528538 · Cited by 13
Neuroimaging-based data-driven subtypes of spatiotemporal atrophy due to Parkinson’s disease
Shawa, Z., Shand, C., Taylor, B., Berendse, H. W., Vriend, C., van Balkom, T. D., van den Heuvel, O. A., van der Werf, Y. D., Wang, J., Tsai, C., et al. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf146 · Cited by 19
Research models to study lewy body dementia
Boschen, S. L., Mukerjee, A. A., Faroqi, A. H., Rabichow, B. E., & Fryer, J. D. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00837-w · Cited by 16
The Role of N6-Methyladenosine (m6A) RNA Modification in the Pathogenesis of Parkinson’s Disease
Wang, Y., Zhao, T., Yuan, C., & Chen, X. (2025) · Biomolecules · doi:10.3390/biom15050617 · Cited by 14
NFκB1: a common biomarker linking Alzheimer's and Parkinson's disease pathology
Cunningham, A., Barrett, E., Risch, S., Lee, P. H. U., Lee, C. M., Moghekar, A., Patra, P., & Shim, J. W. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1589857 · Cited by 14
The integrated control of decision and movement vigor
Thura, D., Haith, A. M., Derosière, G., & Duqué, J. (2025) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2025.07.005 · Cited by 20
Role of Neutrophils in Homeostasis and Diseases
Chang, X., Liu, Y., Qiu, J., & Hua, K. (2025) · MedComm · doi:10.1002/mco2.70390 · Cited by 15
DJ-1/PARK7 in Parkinson’s disease: mechanisms of pathogenesis and therapeutic potential
Bao, W., Ge, Y., Huang, J., Li, Y., Luo, Y., & Huang, N. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.09.025 · Cited by 13
Li, M., Liu, M., & Sha, Y. (2021) · Small · doi:10.1002/smll.202106130 · Cited by 13
Genetic Analysis of HSP40/DNAJ Family Genes in Parkinson’s Disease: a Large Case-Control Study
Zhang, K., Pan, H., Zhao, Y., Wang, Y., Zeng, Q., Zhou, X. C., He, R., Zhou, X., Xiang, Y., Zhou, Z., et al. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02920-5 · Cited by 13
Pizarro-Galleguillos, B., Kunert, L., Brüggemann, N., & Prasuhn, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213678 · Cited by 13
Pharmacogenomics—a New Frontier for Individualized Treatment of Parkinson’s Disease
Liu, J.-S., Chen, Y., Shi, D., Zhang, B., & Pu, J. (2022) · Current Neuropharmacology · doi:10.2174/1570159x21666221229154830 · Cited by 13
Xing, N., Dong, Z., Wu, Q., Zhang, Y., Kan, P., Han, Y., Cheng, X., Wang, Y., & Zhang, B. (2023) · BMC Medical Genomics · doi:10.1186/s12920-023-01481-3 · Cited by 12
Zhao, D., Tian, C., Cheng, M., Yang, F., Tian, C., Liu, Y., Chen, Z., Pang, G., Shen, H., Chang, J. W., et al. (2023) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.142697 · Cited by 13
Virtual Reality for Motor and Cognitive Rehabilitation
Darekar, A. (2023) · Current topics in behavioral neurosciences · doi:10.1007/7854_2023_418 · Cited by 15
Zou, L., Che, Z., Ding, K., Zhang, C., Liu, X., Wang, L., Li, A., & Zhou, J. (2023) · Antioxidants · doi:10.3390/antiox12051134 · Cited by 14
Habets, J., Spooner, R. K., Mathiopoulou, V., Feldmann, L. K., Busch, J. L., Roediger, J., Bahners, B. H., Schnitzler, A., Florin, E., & Kühn, A. A. (2023) · Sensors · doi:10.3390/s23115238 · Cited by 14
A novel plantar pressure analysis method to signify gait dynamics in Parkinson's disease
Sun, Y., Cheng, Y., You, Y., Wang, Y., Zhu, Z., Yu, Y., Han, J., Wu, J., & Yu, N. (2023) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2023601 · Cited by 13
de Batlle, J., Benitez, I. D., Moncusí‐Moix, A., Androutsos, O., Barbastro, R. A., Antonini, A., Arana‐Arri, E., Cabrera-Umpiérrez, M. F., Cea, G., Dafoulas, G., et al. (2023) · Journal of Medical Internet Research · doi:10.2196/42187 · Cited by 13
Corenblum, M. J., McRobbie‐Johnson, A. C. E., Carruth, E., Bernard, K., Luo, M., Mandarino, L., Peterson, S. L., Sans-Fuentes, M. A., Billheimer, D. D., Maley, T. D., et al. (2023) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2023.102501 · Cited by 13
Capecci, M., Cima, R., Barbini, F. A., Mantoan, A., Sernissi, F., Lai, S., Fava, R., Tagliapietra, L., Ascari, L., Izzo, R. N., et al. (2023) · Sensors · doi:10.3390/s23167238 · Cited by 13
Midbrain organoids—development and applications in Parkinson’s disease
Toh, H. S. Y., Choo, X. Y., & Sun, A. X. (2023) · Oxford Open Neuroscience · doi:10.1093/oons/kvad009 · Cited by 14
Abnormalities in Copper Status Associated with an Elevated Risk of Parkinson’s Phenotype Development
Karpenko, M. N., Muruzheva, Z. M., Ilyechova, E. Y., Babich, P. S., & Puchkova, L. V. (2023) · Antioxidants · doi:10.3390/antiox12091654 · Cited by 13
Song, J.-J., Zhao, Y., Shan, X., Luo, Y., Hao, N., & Zhao, L. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148603 · Cited by 14
Santos-Rebouças, C. B., Cotrin, J. C., & dos Santos, G. C. (2023) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2023.111875 · Cited by 16
Zikereya, T., Shi, K., & Chen, W. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1254447 · Cited by 13
Vetchinova, A. S., Рафаилевна, К. М., Ivanov, M. V., Kutukova, K. A., Mudzhiri, N. M., Frumkina, L. E., Васильевич, Б. А., Sukhorukov, V. S., & Illarioshkin, S. N. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45100529 · Cited by 16
MiR-184 Mediated the Expression of ZNF865 in Exosome to Promote Procession in the PD Model
Liu, C., Wang, Y., Li, J., Zhu, X., Jiang, H.-S., Zhao, H., & Zhang, L. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03773-2 · Cited by 13
The Construction and Validation of a Novel Ferroptosis-Related Gene Signature in Parkinson’s Disease
Liu, T., Wu, H., & Wei, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417203 · Cited by 13
Liang, K., Li, X., Guo, Q., Ma, J., Yang, H., Fan, Y., Yang, D., Shi, X., She, Z., Qi, X., et al. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106379 · Cited by 13
Kuo, M., Chu, Y., Yuan, S., Chen, M., & Wu, R. (2024) · Scientific Reports · doi:10.1038/s41598-024-51646-y · Cited by 13
Flanagan, R., Rusch, C. T., Lithander, F. E., & Subramanian, I. (2024) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2024.106021 · Cited by 14
Positron Emission Tomography Imaging of Synaptic Dysfunction in Parkinson’s Disease
Niu, J., Zhong, Y., Jin, C., Cen, P., Wang, J., Cui, C., Xue, L., Cui, X., Tian, M., & Zhang, H. (2024) · Neuroscience Bulletin · doi:10.1007/s12264-024-01188-0 · Cited by 13
The STRAT-PARK cohort: A personalized initiative to stratify Parkinson’s disease
Stige, K. E., Kverneng, S. U., Sharma, S., Skeie, G. O., Sheard, E., Søgnen, M., Geijerstam, S. A. A., Vetås, T., Wahlvåg, A. G., Berven, H., et al. (2024) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2024.102603 · Cited by 14
Beheshti, I., & Ko, J. H. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1375395 · Cited by 17
Zhang, Y., & Zhang, B. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04140-5 · Cited by 13
Netrin-1 signaling pathway mechanisms in neurodegenerative diseases
Zhu, K., Wang, H., Ye, K., Chen, G., & Zhang, Z. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-23-01573 · Cited by 13
Fang, P., Yu, L. W., Espey, H., Agirman, G., Kazmi, S. A., Li, K., Deng, Y., Lee, J., Hrncir, H., Lopez-Romero, A., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06256-9 · Cited by 14
Therapeutic potential of fucoidan in central nervous system disorders: A systematic review
Yang, J., Zhao, H., & Qu, S. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.134397 · Cited by 14
Microglia in Neurodegenerative Diseases
Awogbindin, I. O., Wanklin, M., Verkhratsky, A., & Tremblay, M. (2024) · Advances in neurobiology · doi:10.1007/978-3-031-55529-9_27 · Cited by 14
Poration of mitochondrial membranes by amyloidogenic peptides and other biological toxins
Vassallo, N. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16213 · Cited by 13
Research Progress on the Relationship between Parkinson's Disease and REM Sleep Behavior Disorder
Zhou, Y., Liu, X., & Xu, B. (2024) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2309166 · Cited by 13
Chen, M., Wang, X., Bao, S., Wang, D., Zhao, J., Wang, Q., Liu, C., Zhao, H., & Zhang, C. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.136119 · Cited by 13
Monteiro, J. D. S., Silva, B. B. E., de Oliveira, R. R., Borges, P. G. L. B., Pereira, M. A. O. M., Costa, K. A., Nunes, A. L. S., Telles, J. P. M., & Valênça, M. M. (2024) · Neurosurgical Review · doi:10.1007/s10143-024-02948-2 · Cited by 13
Zhou, H., Li, F., Lin, Z., Meng, L., Chen, D., Zhang, Q., & Niu, L. (2024) · Research · doi:10.34133/research.0516 · Cited by 13
Push-pull effects of basal ganglia network in Parkinson’s disease inferred by functional MRI
Wang, Y., Jiang, Z., Chu, C., Zhang, Z., Wang, J., Li, D., He, N., Fietkiewicz, C., Zhou, C., Kaiser, M., et al. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00835-7 · Cited by 13
Feng, M., Zou, Z., Shou, P., Peng, W., Liu, M., & Li, X. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1479343 · Cited by 14
Xu, J., Dai, P., Zhang, C., Dong, N., Li, C., Tang, C., Jin, Z., Lin, S., Ye, L., Sun, T., et al. (2024) · Advanced Science · doi:10.1002/advs.202412020 · Cited by 14
SynNeurGe: The road ahead for a biological definition of Parkinson's disease
Höglinger, G. U., & Lang, A. E. (2024) · Journal of Parkinson s Disease · doi:10.1177/1877718x241298194 · Cited by 13
Dependence of brain‐tissue R 2 on MRI field strength
van Gelderen, P., Wang, Y., de Zwart, J. A., & Duyn, J. H. (2024) · Magnetic Resonance in Medicine · doi:10.1002/mrm.30400 · Cited by 13
Wang, G., Zhuang, W., Zhou, Y., Wang, X., Li, Z., Liu, C., Li, W., He, M., & Lv, E. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02273-z · Cited by 14
Dou, L., Xu, Z., Xu, J., Zang, C., Su, C., Pieper, A. A., Leverenz, J. B., Wang, F., Zhu, X., Cummings, J. L., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-00870-y · Cited by 21
Aberrant functional connectome gradient and its neurotransmitter basis in Parkinson's disease
Guo, T., Zhou, C., Wen, J., Wu, J., Yan, Y., Qin, J., Xuan, M., Wu, H., Wu, C., Chen, J., et al. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106821 · Cited by 14
Drug Repositioning and Repurposing for Disease-Modifying Effects in Parkinson’s Disease
Jeong, S. H., & Lee, P. H. (2025) · Journal of Movement Disorders · doi:10.14802/jmd.25008 · Cited by 13
Sodium Butyrate ameliorates pain and mood disorders in a mouse model of Parkinson disease
Avagliano, C., Caro, C. D., Cuozzo, M., Roberti, R., Russo, E., Rana, G. L., & Russo, R. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117903 · Cited by 17
Advancements in PROTAC-based therapies for neurodegenerative diseases
Kong, D., Meng, L., Lin, P., & Wu, G. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2463310 · Cited by 14
Xu, S., Kantarcigil, Ç., Rangwala, R., Nellis, A. B., Chun, K. S., Richards, D., Albert-Smet, I., Keller, M., Chen, H., Huang, J., et al. (2025) · Journal of Parkinson s Disease · doi:10.1177/1877718x251329354 · Cited by 13
Gao, X., Luo, Y., Adinkra, E. K., Chen, L., Wei, T., Liu, Y., Guo, M., Wu, C., Wu, C., & Liu, Y. (2025) · Microbial Cell Factories · doi:10.1186/s12934-025-02714-z · Cited by 13
Garon, M., Weck, C. E., Leta, V., Dijkstra, B. W., Muente, C., Gentile, G., Trivedi, D., Groot, M. M., Lorenzl, S., Odin, P., et al. (2025) · Journal of Parkinson s Disease · doi:10.1177/1877718x251321110 · Cited by 13
Self-citationJellen, L. C., Galvis, M. L. E., Sha, Q., Isaguirre, C., Johnson, A., Madaj, Z. B., Lewis, M. M., Sheldon, R. D., Kong, L., Huang, X., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-00949-6 · Cited by 13
Role of mitochondrial quality control in neurodegenerative disease progression
Liu, T., Sun, W., Guo, S., Yuan, Z., Zhu, M., Lu, J., Chen, T., Qu, Y., Feng, C., & Yang, T. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1588645 · Cited by 16
Probing the Pre-diagnostic Phase of Parkinson's Disease in Population-Based Studies
Dommershuijsen, L. J., Boon, A. J. W., & Ikram, M. K. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.702502 · Cited by 13
Termine, A., Fabrizio, C., Strafella, C., Caputo, V., Petrosini, L., Caltagirone, C., Cascella, R., & Giardina, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052557 · Cited by 13
The silver linings of Parkinson’s disease
Cánovas, A. A., Voeten, J., Thomas, O., Gifford, L., Stamford, J., & Bloem, B. R. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00283-1 · Cited by 13
Self-citationHauser, R. A., Giladi, N., Poewe, W. H., Brotchie, J. M., Friedman, H., Oren, S., & Litman, P. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02097-2 · Cited by 13
α-Synuclein PET and Parkinson Disease Therapeutic Trials: Ever the Twain Shall Meet?
Seibyl, J. P. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.263918 · Cited by 13
Dysregulation of Circulatory Levels of lncRNAs in Parkinson’s Disease
Huang, T., Zhao, J.-Y., Pan, R., Jiang, T., Fu, X., Huang, Q. M., Wang, X., Gong, P., Tian, Y., & Zhang, Y. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03086-w · Cited by 13
Exercise-Boosted Mitochondrial Remodeling in Parkinson’s Disease
Magaña, J. C., Deus, C. M., Giné‐Garriga, M., Montané, J., & Pereira, S. P. (2022) · Biomedicines · doi:10.3390/biomedicines10123228 · Cited by 15
Metadata
- Authors
- Bloem, B. R., Okun, M. S., & Klein, C.
- Affiliations
- Radboud University Nijmegen (NL)
- University of Florida Health (US)
- University Hospital Schleswig-Holstein (DE)
- Corresponding author
- Bloem, Bastiaan R
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2021-06
- Volume
- 397
- Issue
- 10291
- Pages
- 2284-2303
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4206481149
- Cited by
- 3,920
- References
- 159
- Citations by year
- 2026: 878 · 2025: 1098 · 2024: 901 · 2023: 607 · 2022: 364 · 2021: 72
- FWCI
- 62.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Funders
- Deutsche Forschungsgemeinschaft
- Parkinson's Foundation (FOR2488)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, neurodegeneration, genetic risk variants, monogenic Parkinson's disease, non-motor symptoms, levodopa, disease-modifying therapy, multidisciplinary care, non-pharmacological treatment, diagnosis, prodromal period
- MeSH terms
- Antiparkinson Agents, Humans, Levodopa, Parkinson Disease, Time Factors, Tremor, Disease Management, Prodromal Symptoms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
